Ankylosing Spondylitis with Peripheral Arthritis After NSAID Failure

Clinical Scenario

This protocol applies to patients with ankylosing spondylitis who have peripheral arthritis — predominantly peripheral joint manifestations alongside the underlying spondyloarthritis.

Prior Treatment — Goals Not Achieved

An initial treatment course — NSAIDs at up to the maximum tolerated dose (used continuously as needed), alongside physiotherapy, regular exercise, education about axSpA, and smoking cessation — failed to achieve the required goal: control of back pain and spinal stiffness within 2–4 weeks.

This protocol represents the structured next step after that failure.

Next-Step Treatment Approach

For patients with peripheral arthritis, a conventional disease-modifying therapy is among the options considered — with specific eligibility criteria and, where clinically appropriate, a targeted local intervention at the affected site.

Full regimen, clinical decision criteria, and sequencing are available in the complete protocol…
Instant Access to Structured Evidence-Based Regimens
References
DOI: 10.1136/ard-2022-223296
Patients with purely axial disease should normally not be treated with csDMARDs; sulfasalazine may be considered in patients with peripheral arthritis.
Glucocorticoid injections directed to the local site of musculoskeletal inflammation may be considered.
In patients with predominantly peripheral manifestations, following recommendations 7 and 8, failure to treatment includes one glucocorticoid injection, if appropriate, and the use of sulfasalazine.
View source ↗